miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities - Wikidata - wikimedia - TriplyDB

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

http://www.wikidata.org/entity/Q28307338

about

MicroRNA-182-5p targets a network of genes involved in DNA repair Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential Epigenomics of leukemia: from mechanisms to therapeutic applications miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1 MicroRNAs in B-cell lymphomas: how a complex biology gets more complex MicroRNAs regulate p21(Waf1/Cip1) protein expression and the DNA damage response in human embryonic stem cells MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemia MicroRNA expression and virulence in pandemic influenza virus-infected mice.MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells.PKCalpha mediated induction of miR-101 in human hepatoma HepG2 cells.Implication of microRNAs in drug resistance for designing novel cancer therapy MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1 MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1.Micromarkers: miRNAs in cancer diagnosis and prognosis.Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells.Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research.miR-34 - a microRNA replacement therapy is headed to the clinic.The functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse.p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression IL-4 Up-Regulates MiR-21 and the MiRNAs Hosted in the CLCN5 Gene in Chronic Lymphocytic Leukemia.Opposite Prognostic Significance of Cellular and Serum Circulating MicroRNA-150 in Patients with Chronic Lymphocytic Leukemia Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia.The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas.MicroRNA profile comparison of the corneal endothelia of young and old mice: implications for senescence of the corneal endothelium Non-coding RNAs and cancer.The Role of miRNA in Haematological Malignancy.Protective effects of vitamin C and vitamin E against hysterosalpingography-induced epithelial degeneration and proliferation in rat endometrium.The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia.The coming of age of microRNA for B cell lymphomas.DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family.Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia.DNA methylation of microRNA genes in multiple myeloma.Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies.Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia.

P2860

Q24633326-47118C0D-B0CA-4F3A-8F02-40D2211A6006 Q24633394-1BFE06A2-7BAA-4959-951D-5CC3E73BB0D9 Q26797469-01F113C4-92E2-49E5-A3D8-51008E458E0C Q26823403-C6C802DB-1A0A-4C44-BBB7-5DC1648C5380 Q28239225-E6FA9077-643B-467C-8954-97B9D6E58062 Q28254647-7C66FF0A-A6F0-41B2-90FB-D458C19A4BA8 Q28264713-BC120C61-C3A3-4752-BAFF-8A2ED1088D52 Q28289170-243A1DD3-CA09-4D7D-9F11-7F6430CE4358 Q28303339-3BB56C74-C9FD-46C3-BB75-2A150FB5399D Q30384382-BC5C0F4F-AB76-44E7-8B7B-A818358CD235 Q30537249-B37069D2-618B-4FB4-BD76-FF47B8F86189 Q33574184-177D9CD8-1FB3-436D-91AB-F8A15C4E9999 Q33780259-4CE9D94F-B814-44A3-AACA-43EB16B2F99F Q33847322-CAAC772F-36F6-4887-8729-7D5B470D3A23 Q33870086-9CF65452-7725-448D-9FDA-0C8241B08EC1 Q33903223-FCEEED4A-EAAA-40BB-A172-E78B91CAFE3B Q33994431-45F2AF9D-F26D-4381-A416-3098126B18A7 Q34024981-268D02CB-507F-4188-9F80-9BEECD934DB4 Q34108602-BB1A143A-78EA-4B08-A41A-26C90DA2E63B Q34146733-BBC6B567-E972-4D2D-988C-E2E62CC629E4 Q34283589-1E230D94-879B-433D-BEB1-51053581FB65 Q34640230-E46636C3-2F13-4C38-9B13-CDE1014D3075 Q34806020-B5435DFC-95C0-4CE3-851F-A7654931F824 Q35503066-0F1A2D00-28ED-410E-90DC-01F7E4267B4E Q35613623-B460879D-90E6-4F70-A09E-93BD21B4B20E Q35707206-D665151E-BF60-47A6-B0A4-82419FE6A364 Q36022313-322C389C-E439-4D50-8792-D8C5A6D68593 Q36956179-2F5507FA-509E-4AE3-8A1C-A8300009CE25 Q37041036-2BB0952E-4765-4857-A4F2-194D49D3A08D Q37091622-1ED04A90-412C-47B0-ACCF-0F4CC8C7AC70 Q37139278-21E261B0-C350-4EEF-B6BF-C2B559A23742 Q37422388-1284E64E-ACE8-40B1-BDDD-FD89A3B3CDE3 Q37518141-0466A435-D4A6-4F87-AC56-EC04A834EF74 Q37747342-5F955CED-6AA0-48BC-8D12-F6628EE31CDB Q37831954-183AAB08-2084-48E4-AF9B-1599FC446384 Q37962577-04ED5DA5-5920-47F0-A6D3-71919D3D2078 Q37978967-37AED451-D6C0-4A55-8F67-34EED3C19725 Q38020153-ECBC65ED-5695-42DB-8EAE-962F14869C0A Q38059899-444A297E-ACA2-402F-962B-8F6DD9BAC5D2 Q38101382-FFDE3258-9865-4B80-BBF9-C4E1C63C5B84

P2860

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

http://www.wikidata.org/entity/Q28307338

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

@ast

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

@en

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

@nl

type

label

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

@ast

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

@en

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

@nl

prefLabel

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

@ast

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

@en

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

@nl

P1433

Q28307338-99075D6A-16E9-48E1-A8BE-F27398EDCED9

P1476

Q28307338-57D89F7E-C4CE-4672-9A62-C59017CBA816

P2093

Q28307338-2D1A10E4-4CB1-41FC-BC99-52473F201814

Q28307338-35B558FB-39E3-4347-8F8D-B0F79AEFF35D

Q28307338-4BFC9090-94F7-4A97-8857-0E24D6909FDC

Q28307338-72541B69-5BBD-4894-9861-A2663C8B8FD7

Q28307338-8845F9AC-4153-4DA6-9930-064CF48197D0

Q28307338-8EC51041-7FD8-47CC-B197-6C94DCD4E8A9

Q28307338-B01BC6F8-7FA1-46ED-9C91-736B8553C6E5

Q28307338-B1A6C3D1-C55A-4BA6-B3CC-912D25846395

Q28307338-B2EC0665-2BA4-4D82-A9C4-53F995303628

Q28307338-B6A26C45-AE0F-4C3D-AAED-42F866A17F0F

P2888

Q28307338-8A74006A-7F05-424E-956B-770E98098951

P304

Q28307338-B375D304-4051-4E1B-8939-2C9CBD3B4F0A

P31

Q28307338-66093329-31CF-426A-B118-BE87B5A8D94D

P356

Q28307338-6FDAE938-B6B9-478E-B0A8-E630D7305E5A

P407

Q28307338-43F3169F-67A3-4D5A-B635-28FC5038DDFD

P433

Q28307338-0BE937FF-AF6A-4E1F-AC9C-A7A3267B76DE

P478

Q28307338-968790F9-DB94-47C1-ADCC-0D015FEE4704

P50

Q28307338-23FBCF4F-8E2F-4326-A806-A89269078170

P577

Q28307338-DE738B86-088D-4982-8EA8-F3406ABF22E1

P5875

Q28307338-9B0DB8C8-1A7B-4BA8-8779-EC6C82FFE58F

P6179

Q28307338-6A786698-25E7-49C5-918F-2381EB94D659

P698

Q28307338-18832A82-88C5-4300-B205-BCCC638909AE

P356

P1433

P1476

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

@en

P2093

B Tichy

http://www.w3.org/2001/XMLSchema#string

J Kotaskova

http://www.w3.org/2001/XMLSchema#string

J Malcikova

http://www.w3.org/2001/XMLSchema#string

J Mayer

http://www.w3.org/2001/XMLSchema#string

J Smardova

http://www.w3.org/2001/XMLSchema#string

K Malinova

http://www.w3.org/2001/XMLSchema#string

K Stano Kozubik

http://www.w3.org/2001/XMLSchema#string

M Doubek

http://www.w3.org/2001/XMLSchema#string

M Mraz

http://www.w3.org/2001/XMLSchema#string

M Trbusek

http://www.w3.org/2001/XMLSchema#string

P2888

P304

1159-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2008.377

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23807414

http://www.w3.org/2001/XMLSchema#string

P6179

1015089220

http://www.w3.org/2001/XMLSchema#string

P698

19158830

http://www.w3.org/2001/XMLSchema#string